MedDataX Logo

Cost-consequence Analysis of Influenza Vaccination in a Teaching Hospital in Rome

NCT ID: NCT06304038

Last Updated: 2024-03-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

5483 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-10-16

Study Completion Date

2019-11-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Flu vaccination, as well as being effective to prevent seasonal influenza, decreases staff illness and absenteeism and reduces costs resulting from loss of productivity. Despite the effectiveness of flu vaccination, the seasonal coverage among healthcare workers is usually low. The aim of this retrospective observational study is to analyze the vaccination coverage rate among all employees (healthcare workers and administrative staff) of a large teaching hospital in Rome during the 2017-2018 influenza season, to perform a cost-consequence analysis of influenza vaccination (by evaluating the absenteeism due to illness in the epidemic period), and to assess the impact of vaccination in terms of both costs and sick days.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of the Effectiveness of a Flu Vaccination Campaign for Healthcare Workers of a Teaching Hospital: a Pre-post Study

NCT05783713

Influenza Vaccination
COMPLETED

Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza

NCT01693380

Influenza Acute Respiratory Infection
COMPLETED PHASE4

Evaluation of a School-based Influenza Vaccination Program

NCT00961337

Influenza Influenza Vaccines
COMPLETED PHASE4

Evaluation of the Effectiveness of Vaccination With 2009 H1N1 Vaccines During Influenza Season 2010-11

NCT01206114

Influenza Caused by the 2009 H1N1 Influenza Virus
COMPLETED

Impact of Patient Education on Influenza Vaccine Uptake Among Community-dwelling Chinese Elderly

NCT02741843

Influenza, Human
COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Influenza Vaccine Cost-Benefit Analysis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccinated subjects

Healthcare workers that received quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra in a single administration

Flu Vaccine

Intervention Type DRUG

Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra

Unvaccinated subjects

Healthcare workers that did not received flu vaccine

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Flu Vaccine

Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Healthcare workers at Fondazione Policlinico Universitario "A.Gemelli" IRCCS

Exclusion Criteria

• Healthcare workers not working at Fondazione Policlinico Universitario "A.Gemelli" IRCCS
Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Laurenti Patrizia

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fondazione Policlinico Universitario "A.Gemelli" IRCCS

Rome, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2018

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Financing Strategies of Influenza Vaccination in China
NCT04038333 COMPLETED
A Study to Describe Pediatric Influenza Vaccine Coverage
NCT00639418 COMPLETED
Incentives for Influenza Vaccination
NCT06300242 COMPLETED NA
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years
NCT00537524 COMPLETED PHASE2
Immune Responses in Health Care Personnel
NCT03323112 RECRUITING
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older
NCT00329966 COMPLETED PHASE2
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine for the Elderly
NCT00938392 COMPLETED PHASE3
Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10
NCT00992212 COMPLETED PHASE2
Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudges in Increasing InFLUenza Vaccine Uptake Among Older Adults
NCT06030726 COMPLETED NA
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to NON Elderly AND Elderly Subjects
NCT00518726 COMPLETED PHASE2
The Effect of a Planning Prompt on Seasonal Influenza Vaccination Rates
NCT01207232 COMPLETED NA
Protection From Influenza: Determining the Impact of Prior Infection
NCT03004040 UNKNOWN
Evaluation of Pandemic Vaccination Campaign
NCT01024725 COMPLETED
Safety and Immunogenicity of One Dose of an Inactivated Trivalent Sub-unit Influenza Vaccine Administered to Non-elderly Adult and Elderly Subjects
NCT01357265 COMPLETED PHASE2
Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2007/2008) When Administered to Elderly Subjects
NCT00522236 COMPLETED PHASE2
A Study to Evaluate the Safety, Tolerability and Immunogenicity of a Universal Influenza A Vaccine
NCT01265914 COMPLETED PHASE1
Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge
NCT02071329 COMPLETED PHASE1/PHASE2
Cost-effectiveness of the Influenza Vaccination
NCT05996549 UNKNOWN PHASE4
Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2010-2011
NCT01152814 COMPLETED PHASE2
Safety and Immunogenicity of One Dose of a Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture Administered to Adult and Elderly Subjects
NCT01422512 COMPLETED PHASE3
Effect of Influenza Vaccination of Healthcare Workers (HCW) on the Risk of Influenza in Patients Hospitalized in Short Stays Units
NCT02198638 COMPLETED NA
Direct and Indirect Benefits of Influenza Vaccination in Schools and Households
NCT00981513 COMPLETED PHASE4
Brief Influenza Vaccine Education to Pregnant Women
NCT01772901 COMPLETED NA
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
NCT00616928 COMPLETED PHASE3
Safety and Immunogenicity of Three Commercially Available Influenza Vaccines in Children Aged 6 to <36 Months
NCT00311428 COMPLETED PHASE4